EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Oncternal Therapeutics's enterprise value is $-9.52 Mil.
Oncternal Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Oncternal Therapeutics's EV-to-Revenue for today is .
The historical rank and industry rank for Oncternal Therapeutics's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Oncternal Therapeutics was 228.06. The lowest was -38.73. And the median was -29.30.
ONCT's EV-to-Revenue is not ranked *
in the Biotechnology industry.
Industry Median: 7.66 * Ranked among companies with meaningful EV-to-Revenue only.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Oncternal Therapeutics's EV-to-Revenue
For the Biotechnology subindustry, Oncternal Therapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Oncternal Therapeutics's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Oncternal Therapeutics's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Oncternal Therapeutics's EV-to-Revenue falls into.
Oncternal Therapeutics's current Enterprise Value is $-9.52 Mil.
Oncternal Therapeutics's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncternal Therapeutics's share price for today is $8.29.
Oncternal Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Oncternal Therapeutics EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Oncternal Therapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Oncternal Therapeutics (Oncternal Therapeutics) Business Description
Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that targets ROR1 and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ONCT has been successfully added to your 